HomeEW • NYSE
Edwards Lifesciences Corp
Follow
In the news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 1.39B | 9.43% |
Operating expense | 739.70M | 53.62% |
Net income | 385.60M | 4.24% |
Net profit margin | 27.82 | -4.76% |
Earnings per share | 0.59 | -7.81% |
EBITDA | 396.50M | -30.51% |
Effective tax rate | 11.56% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 3.98B | 143.50% |
Total assets | 13.06B | 39.43% |
Total liabilities | 2.99B | 13.19% |
Total equity | 10.06B | — |
Shares outstanding | 587.90M | — |
Price to book | 4.03 | — |
Return on assets | 6.80% | — |
Return on capital | 8.39% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | 385.60M | 4.24% |
Cash from operations | -127.50M | -193.34% |
Cash from investing | -576.70M | -4,190.07% |
Cash from financing | 28.60M | 106.92% |
Net change in cash | -624.60M | -134.90% |
Free cash flow | -218.19M | -403.94% |
Previous close
$68.51
Day range
$67.53 - $68.92
Year range
$58.93 - $96.12
Market cap
40.27B USD
Avg Volume
4.39M
P/E ratio
29.26
Dividend yield
-
Primary exchange
NYSE
About
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the SAPIEN transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; the Dominican Republic; Puerto Rico; and Singapore; and is building a new facility due to be completed in 2021 in Limerick, Ireland. Wikipedia
Founded
1958
Headquarters
Website
Employees
15,800
